Format

Send to

Choose Destination
Indian J Ophthalmol. 2019 Jul;67(7):1109-1113. doi: 10.4103/ijo.IJO_1532_18.

Bevacizumab versus ziv-aflibercept in branch retinal vein occlusion.

Author information

1
Department of Surgery, School of Medicine and Dentistry, University of Ghana; Eye Centre, Korle-Bu Teaching Hospital, Korle-Bu, Accra, Ghana.
2
Smt. Kanuri Santhamma Centre for Vitreo-Retinal Diseases, L V Prasad Eye Institute, Hyderabad; Retina and Uveitis Department, GMR Varalakshmi Campus, LV Prasad Eye Institute, Hanumanthawaka Junction, Visakhapatnam, Andhra Pradesh, India.
3
Smt. Kanuri Santhamma Centre for Vitreo-Retinal Diseases, L V Prasad Eye Institute, Hyderabad, India.
4
Department of Ophthalmology, American University of Beirut; Department of Ophthalmology, Rafik Hariri University Hospital, Beirut, Lebanon.

Abstract

Purpose:

To compare the effectiveness of treatment with intravitreal bevacizumab (IVB) and ziv-aflibercept (IVZ) in patients with macular edema (ME) post-branch retinal vein occlusion (BRVO).

Methods:

Patients with treatment naïve ME post-BRVO were included retrospectively if they received either IVB (0.05 ml/1.25 mg) or IVZ (0.05 ml/1.25 mg) monotherapy with a follow up of 12 months.

Results:

Thirty-two and 17 eyes received IVB and IVZ, respectively. The mean improvement in best corrected visual acuity (BCVA) was 0.36 ± 0.3 logarithm of minimum angle of resolution (logMAR) in the IVB group and 0.27 ± 0.3 in the IVZ group (P = 0.35). The mean change in central macular thickness was 178.9 ± 180.9 and 173.5 ± 344.4 μm in IVB and IVZ groups, respectively (P = 0.94). The mean number of injections was higher in the IVB group (4.0 ± 1.8) compared with 1.82 ± 0.8 in the IVZ group (P < 0.0001). The IVZ group had significantly fewer number of visits (P < 0.0001) and longer maximum treatment-free intervals (P = 0.0081).

Conclusion:

IVZ appears to be cost-effective with the similar visual outcome and less number of visits in comparison to IVB.

KEYWORDS:

Branch retinal venous occlusion; Ziv-aflibercept; bevacizumab; macular edema; optical coherence tomography

PMID:
31238422
DOI:
10.4103/ijo.IJO_1532_18
Free PMC Article

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center